Equities research analysts forecast that Acceleron Pharma Inc (NASDAQ:XLRN) will report $4.35 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Acceleron Pharma’s earnings, with the lowest sales estimate coming in at $3.05 million and the highest estimate coming in at $6.39 million. Acceleron Pharma posted sales of $3.71 million in the same quarter last year, which would indicate a positive year over year growth rate of 17.3%. The company is expected to announce its next quarterly earnings results on Monday, May 14th.
According to Zacks, analysts expect that Acceleron Pharma will report full-year sales of $4.35 million for the current fiscal year, with estimates ranging from $13.20 million to $42.96 million. For the next fiscal year, analysts anticipate that the business will post sales of $83.71 million per share, with estimates ranging from $17.40 million to $170.19 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Acceleron Pharma.
Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). Acceleron Pharma had a negative net margin of 804.49% and a negative return on equity of 38.71%. The firm had revenue of $3.71 million for the quarter, compared to the consensus estimate of $3.39 million.
A number of research analysts have weighed in on XLRN shares. HC Wainwright reiterated a “buy” rating and set a $62.00 price objective on shares of Acceleron Pharma in a research report on Monday, December 11th. BidaskClub upgraded shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, February 15th. Credit Suisse Group reiterated a “buy” rating and set a $55.00 price objective on shares of Acceleron Pharma in a research report on Friday, March 2nd. Cann reiterated a “hold” rating on shares of Acceleron Pharma in a research report on Monday, January 8th. Finally, Oppenheimer reiterated a “hold” rating on shares of Acceleron Pharma in a research report on Monday, January 8th. Two analysts have rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $47.06.
In related news, Director Jean George sold 105,122 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $35.73, for a total value of $3,756,009.06. Following the completion of the sale, the director now directly owns 1,250 shares of the company’s stock, valued at $44,662.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard F. Pops sold 37,500 shares of the company’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $41.42, for a total transaction of $1,553,250.00. Following the completion of the sale, the director now directly owns 68,750 shares of the company’s stock, valued at $2,847,625. The disclosure for this sale can be found here. Insiders have sold 183,521 shares of company stock valued at $7,082,848 over the last three months. Insiders own 3.90% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Xact Kapitalforvaltning AB purchased a new stake in Acceleron Pharma in the fourth quarter worth about $217,000. MetLife Investment Advisors LLC purchased a new stake in Acceleron Pharma in the fourth quarter worth about $739,000. TIAA CREF Investment Management LLC lifted its stake in Acceleron Pharma by 3.8% in the fourth quarter. TIAA CREF Investment Management LLC now owns 87,027 shares of the biopharmaceutical company’s stock worth $3,693,000 after acquiring an additional 3,178 shares during the period. Teachers Advisors LLC lifted its stake in Acceleron Pharma by 36.7% in the fourth quarter. Teachers Advisors LLC now owns 80,066 shares of the biopharmaceutical company’s stock worth $3,398,000 after acquiring an additional 21,508 shares during the period. Finally, California State Teachers Retirement System lifted its stake in Acceleron Pharma by 14.5% in the fourth quarter. California State Teachers Retirement System now owns 59,177 shares of the biopharmaceutical company’s stock worth $2,511,000 after acquiring an additional 7,499 shares during the period. 88.21% of the stock is owned by institutional investors.
Acceleron Pharma (XLRN) opened at $44.23 on Thursday. Acceleron Pharma has a 1 year low of $24.37 and a 1 year high of $46.93. The firm has a market cap of $2,000.00, a price-to-earnings ratio of -16.44 and a beta of 1.39.
WARNING: “Zacks: Analysts Expect Acceleron Pharma Inc (XLRN) Will Post Quarterly Sales of $4.35 Million” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/03/15/zacks-analysts-expect-acceleron-pharma-inc-xlrn-will-post-quarterly-sales-of-4-35-million.html.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.